The Miracle Drug and Its Early Warning
Alexander Fleming’s 1928 discovery of penicillin is one of medicine’s best-known breakthroughs, but far less famous is a warning Fleming himself delivered less than two decades later, in his 1945 Nobel Prize acceptance speech. Fleming cautioned that improper use of penicillin — specifically, exposing bacteria to doses too low to kill them outright — could allow resistant strains to develop and spread, effectively predicting the central mechanism of antibiotic resistance before the phenomenon had become a widespread clinical problem. His warning proved prescient almost immediately: penicillin-resistant strains of Staphylococcus aureus, the bacterium the original antibiotic had been so effective against, were already being documented in hospitals by the late 1940s, just a few years after the drug reached mass production.
The underlying mechanism Fleming anticipated is a straightforward case of natural selection operating on a fast timescale. Bacteria reproduce rapidly and occasionally develop random genetic mutations; when an antibiotic is present, any bacteria that happen to carry a mutation allowing them to survive it — by breaking down the drug, altering the target it binds to, or pumping it back out of the cell — are the ones left to reproduce, passing that resistance on to the next generation. Incomplete antibiotic courses, agricultural antibiotic overuse, and the sheer number of bacterial generations that can occur in a short time all accelerate the same basic evolutionary process, which is why resistance tends to emerge fastest in settings, like hospitals, where antibiotic use is heaviest and most sustained, and where the sheer density of vulnerable patients gives any resistant strain that does emerge an unusually easy path to spread further.
An Ongoing Arms Race
Methicillin, a modified form of penicillin designed specifically to overcome the resistance mechanism common staph strains had developed, was introduced in 1959 — and methicillin-resistant Staphylococcus aureus, now widely known as MRSA, was already documented in the United Kingdom by 1961, just two years later. MRSA’s continued spread through hospitals and, eventually, community settings over the following decades made it one of the most closely tracked examples of antibiotic resistance in modern medicine, and it remains a significant concern in healthcare settings today. Vancomycin, long considered a reliable treatment option for resistant staph infections, faced its own resistance challenge when vancomycin-resistant enterococci were first identified in the late 1980s, followed by fully vancomycin-resistant Staphylococcus aureus strains documented in the early 2000s — each new resistant strain effectively closing off another treatment option and narrowing the remaining arsenal.
The World Health Organization has formally identified antimicrobial resistance as one of the top public health threats facing humanity, reflecting a growing recognition among public health researchers that the pace of new antibiotic development has slowed considerably since the mid-twentieth century “golden age” of antibiotic discovery, even as resistance continues to spread. That imbalance has driven the modern concept of antibiotic stewardship — coordinated efforts by hospitals and health systems to ensure antibiotics are prescribed only when necessary, at the correct dose, and for the correct duration — a direct, institutionalized response to the exact mechanism Alexander Fleming warned about in a five-minute Nobel lecture in 1945.
Source: National Institutes of Health (NIH), Encyclopaedia Britannica, and the World Health Organization.